Association of HER1 amplification with poor prognosis in well differentiated gastric carcinomas

Journal of Clinical Pathology

Volumn 67, Issue 4, 2014, Pages 307-312

  Kandel, Christine ^a,b   Leclair, François ^b   Bou Hanna, Chantal ^a   Laboisse, Christian L ^a,b   Mosnier, Jean François ^a,b,c  

^a UNIVERSITÉ DE NANTES   (France)

^b NANTES UNIVERSITY HOSPITAL   (France)

^c Institut du Cancer Nantes Atlantique   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CERB 2; EGFR; GASTRIC CANCER; HISTOPATHOLOGY; IN SITU HYBRIDISATION;

ADULT; AGED; AGED, 80 AND OVER; CADHERINS; CARCINOMA; FEMALE; FOLLOW-UP STUDIES; FRANCE; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; MALE; MIDDLE AGED; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; STOMACH NEOPLASMS; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84898800878     PISSN: 00219746     EISSN: 14724146     Source Type: Journal    
DOI: 10.1136/jclinpath-2013-201726     Document Type: Article

References (28)

1. Lauwers GY, Carneiro F, Graham DY, et al. Gastric carcinomas. In: Bosman BT, Carneiro F, Hruban RH, Theise ND, eds. WHO classification of tumours of the digestive system. Lyon: International Agency for Research on Cancer, 2010:48-58.
2. Perl AK, Wilgenbus P, Dahl U, et al. A causal role for E-cadherin in the transition from adenoma to carcinoma. Nature 1998;392:190-3.
3. Hajra KM, Fearon ER. Cadherin and catenin alterations in human cancer. Genes Chromosomes Cancer 2002;34:255-68.
4. Takehana T, Kunitomo K, Suzuki S, et al. Expression of epidermal growth factor receptor in gastric carcinomas. Clin Gastroenterol Hepatol 2003;1:438-45.
5. Takehana T, Kunitomo K, Kono K, et al. Status of cerbB-2 in gastric adenocarcinoma: a comparative study of immunohistochemistry, fluorescence in situ hybridization and enzyme-linked immuno-sorbent assay. Int J Cancer 2002;98:833-7.
6. Takeichi M. Cadherin cell adhesion receptor as a morphogenetic regulator. Science 1991;251:1451-5.
7. Becker KF, Atkinson MJ, Reich U, et al. E-cadherin gene mutations provide clues to diffuse type gastric carcinomas. Cancer Res 1994;54:3845-52.
8. Becker KF, Hofler H. Frequent somatic allelic inactivation of the E-cadherin gene in gastric carcinomas. J Natl Cancer Inst 1995;87:1082-4.
9. Muta H, Noguchi M, Kanai Y, et al. E-cadherin gene mutations in signet ring cell carcinoma of the stomach. Jpn J Cancer Res 1996;87:843-8.
10. Guilford PJ, Hopkins J, Harraway J, et al. E-cadherin germline mutations in familial gastric cancer. Nature 1998:392:402-5.
11. Mayer B, Jonhson JP, Leitl F, et al. E-cadherin expression in primary and metastatic gastric cancer: down-regulation correlates with cellular dedifferentiation and glandular disintegration. Cancer Res 1993;53:1690-5.
12. Jawhari A, Jordan S, Poole S, et al. Abnormal immunoreactivity of the E-cadherin-catenin complex in gastric carcinoma: relationship with patient survival. Gastroenterology 1997;112:46-54.
13. Lemoine NR, Jain S, Silvestre F, et al. Amplification and overexpression of the EGF receptor and c-erbB-2 proto-oncogenes in human stomach cancer. Br J Cancer 1991;64:79-83.
14. Kimura M, Tsuda H, Morita D, et al. A proposal for diagnostically meaningful criteria to classify increased epidermal growth factor receptor and c-erbB-2 gene copy numbers in gastric carcinoma, based on correlation of fluorescence in situ hybridization and immunohistochemical measurements. Virchows Arch 2004;445:255-62.
15. Mitsui F, Dobashi Y, Imoto I, et al. Non-incidental coamplification of Myc and ERBB2, and Myc and EGFR, in gastric adenocarcinomas. Mod Pathol 2007;20:622-31.
16. Kim MA, Lee HS, Lee HE, et al. EGFR in gastric carcinomas: prognostic significance of protein overexpression and high gene copy number. Histopathology 2008;52:738-46.
17. Allgayer H, Babic R, Gruetzner KU, et al. c-erbB-2 is of independent prognostic relevance in gastric cancer and is associated with the expression of tumour-associated protease systems. J Clin Oncol 2000;18:2201-9.
18. Bryant DM, Stow JL. The ins and outs of E-cadherin trafficking. Trends Cell Biol 2004;14:427-34.
19. Najy AJ, Day KC, Day ML. The ectodomain shedding of E-cadherin by ADAM15 supports ErbB receptor activation. J Biol Chem 2008;283:18393-401.
20. Hoschuetzky H, Aberle H, Kemler R. Beta-catenin mediates the interaction of the cadherin-catenin complex with epidermal growth factor receptor. J Cell Biol 1994;127:1375-80.
21. Witta SE, Gemmill RM, Hirsch FR, et al. Restoring E-cadherin expression increases sensitivity to epidermal growth factor receptor inhibitors in lung cancer cell lines. Cancer Res 2006;66:944-50.
22. American Joint Committee on Cancer (AJCC). AJCC Cancer Staging Manual. 7th edn. Edge SB, Byrd DR, Carducci MA, Compton CC, Fritz AG, Greene F, Trotti A, eds. New York: Springer, 2009.
23. Lauren P. The two histological main types of gastric carcinoma and so-called intestinal-type carcinoma. An Attempt at a histo-clinical classification. Acta Pathol Microbiol Scand 1965;64:31-49.
24. Reiter JL, Mailhe NJ. Characterization and expression of novel 60-kDa and 110 kDa EGFR isoforms in human placenta. Ann NY Acad Sci 2003;995:35-47.
25. Blanchot-Jossic F, Jarry A, Masson D, et al. Up-regulated expression of ADAM17 in human colon carcinoma: co-expression with EGFR in neoplastic and endothelial cells. J Pathol 2005;207:156-63.
26. Hofmann M, Stoss O, Shi D, et al. Assessment of a HER2 scoring system for gastric cancer: results from a validation study. Histopathology 2008;52:797-805.
27. Mosnier JF, Jarry A, Bou-Hanna C, et al. ADAM15 upregulation and interaction with multiple binding partners in inflammatory bowel disease. Lab Invest 2006;86:1064-73.
28. Almeida PR, Ferreira VA, Santos CC, et al. E-cadherin immunoexpression patterns in the characterisation of gastric carcinoma histotypes. J Clin Pathol 2010:63:635-9.